The moves, to lower the cost of a drug prescribed to women going through IVF and boost employer coverage, follow Trump’s campaign promise to make fertility care more accessible.

In a bid to fulfill President Trump’s campaign promise of making fertility care more accessible, the White House has taken significant steps to lower the cost of a drug commonly prescribed to women undergoing in vitro fertilization (IVF) and enhance employer coverage for such treatments.

Lowering the Cost of IVF Medication

One of the key initiatives undertaken by the White House is aimed at reducing the financial burden on women going through IVF by making the medication used in the process more affordable. This move is expected to make it easier for individuals and couples struggling with infertility to access the treatment they need without facing exorbitant costs.

Boosting Employer Coverage for Fertility Treatments

Additionally, the White House has also focused on improving employer coverage for fertility treatments, including IVF. By working with businesses and insurance providers, the administration aims to ensure that more individuals have access to comprehensive and affordable reproductive healthcare options through their workplace benefits.

Supporting Women’s Reproductive Health

These efforts reflect a broader commitment to supporting women’s reproductive health and addressing the challenges faced by those seeking fertility care. By making these treatments more accessible and affordable, the White House is striving to empower individuals to pursue their family planning goals and overcome obstacles related to infertility.

Overall, the initiatives taken by the White House underscore the importance of prioritizing reproductive healthcare and making it more equitable for all individuals. By focusing on lowering costs and expanding coverage for fertility treatments, the administration is taking concrete steps towards fulfilling its promise of making fertility care more accessible to those in need.